Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …

The 2016 revised fourth edition of the World Health Organization (WHO) classification of
central nervous system (CNS) tumors incorporated molecular features with histologic …

Gain-of-function mutations in isocitrate dehydrogenase (IDH) in human cancers result in the
production of d-2-hydroxyglutarate (d-2HG), an oncometabolite that promotes tumorigenesis …

Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and
have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in …

BACKGROUND Metabolic reprogramming is a hallmark of malignancy first recognized a
century ago. In some cases, reprogrammed metabolic activities can be exploited to …

Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate
and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances …

Single-cell RNA sequencing has revealed extensive transcriptional cell state diversity in
cancer, often observed independently of genetic heterogeneity, raising the central question …

DNA methylation is of paramount importance for mammalian embryonic development. DNA
methylation has numerous functions: it is implicated in the repression of transposons and …

Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …